StockData

CRISPR Therapeutics vs Intellia Therapeutics

CRSP and NTLA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CRSP and NTLA compare

CRISPR Therapeutics is the larger company, worth 2.8 times as much as Intellia Therapeutics ($3.9B against $1.4B).

Intellia Therapeutics grew revenue faster over the last twelve months (12.6% versus −64.8% for CRISPR Therapeutics).

Intellia Therapeutics keeps more of each dollar of sales as profit, with a net margin of −672% compared with −3369% at CRISPR Therapeutics.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCRSPNTLA
Size and price
Market cap$3.9B$1.4B
Share price$40.15$9.78
Change, 1 year−23.6%12.4%
Change, 5 years−49.0%−91.4%
Beta (5Y)1.591.65
Employees393377
StockData Score
Total score88
Valuation score01 (better)
Growth score11
Performance score2 (better)1
Health score55
Dividend score00
Valuation
P/S290×23.0× (better)
P/B2.2×1.9× (better)
FCF yield−9.6% (better)−25.4%
Fair value–$9.13
Margin of safety–−7.2%
Growth
Revenue growth (TTM)−64.8%12.6% (better)
Revenue growth, 5Y average37.3% (better)3.1%
Profitability
Operating margin−3990%−712% (better)
Net margin−3369%−672% (better)
FCF margin−2773%−586% (better)
Return on equity−26.1% (better)−6425%
Financial health
Debt / equity0.000.00
Current ratio17.85 (better)6.65
Altman Z-score1.79 (better)0.86
Piotroski F-score23 (better)
Dividends and buybacks
Buyback yield−10.0%–
Shareholder yield−10.0%0.00% (better)
Ownership
Held by institutions78.9%103%
Held by insiders2.7%2.0%
Insider net buying, 12 months−$17.9M−$869K (better)
Short interest, % of float18.3%32.3%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.